drugset / Trial / NCT01265433

Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy

NCT01265433

RandomizedParallel-groupDouble-blindTreatment

Summary

Study of galinpepimut-S, a Wilms Tumor-1 (WT1) vaccine, to see if it delays or prevents the mesothelioma from growing back after surgery. WT1 is a protein in cancer cells that regulates gene expression and causes cell growth.

Timeline

Start
2010-12-21
Primary completion
2016-11-30
Completion
2017-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Galinpepimut-S Vaccine Subcutaneous
Background Montanide Other / unclassified 1 ml Subcutaneous
Background sargramostim Protein / enzyme biologic 70 ug Subcutaneous